Long-acting injectable cabotegravir for HIV prevention: what do we know and need to know about the risks and consequences of cabotegravir resistance?
UM Parikh, CA Koss, JW Mellors - Current HIV/AIDS Reports, 2022 - Springer
Abstract Purpose of Review Cabotegravir is a potent integrase strand transfer inhibitor
(INSTI) recently approved as a long-acting injectable formulation for HIV prevention (CAB …
(INSTI) recently approved as a long-acting injectable formulation for HIV prevention (CAB …
Safety and efficacy of long-acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition
VA Fonner, K Ridgeway, A Van Der Straten… - Aids, 2023 - journals.lww.com
Objective: HIV remains a significant burden, despite expanding HIV prevention tools. Long-
acting injectable cabotegravir (CAB-LA) is a new preexposure prophylaxis (PrEP) product …
acting injectable cabotegravir (CAB-LA) is a new preexposure prophylaxis (PrEP) product …
Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among …
Background Half of new HIV acquisitions in Africa occur in adolescent girls and young
women. Pre-exposure prophylaxis (PrEP) with oral tenofovir disoproxil fumarate plus …
women. Pre-exposure prophylaxis (PrEP) with oral tenofovir disoproxil fumarate plus …
Control groups for HIV prevention efficacy trials: what does the future hold?
H Janes, S Buchbinder - Current Opinion in HIV and AIDS, 2023 - journals.lww.com
Efficacy trials of new HIV prevention interventions are feasible but require careful
consideration, given the complexity and dynamic state of the prevention field. While …
consideration, given the complexity and dynamic state of the prevention field. While …
Factors that influence adolescent girls and young women's re‐initiation or complete discontinuation from daily oral PrEP use: a qualitative study from Eastern Cape …
Introduction Adolescent girls and young women (AGYW) face barriers that jeopardize their
prevention‐effective use of daily oral pre‐exposure prophylaxis (PrEP). We sought to …
prevention‐effective use of daily oral pre‐exposure prophylaxis (PrEP). We sought to …
Voluntary licensing of long‐acting HIV prevention and treatment regimens: using a proven collaboration‐and competition‐based mechanism to rapidly expand at …
L Gaayeb, A Das, I James, R Murthy… - Journal of the …, 2023 - Wiley Online Library
Introduction Emerging long‐acting (LA) prevention and treatment medicines, technologies
and regimens could be game‐changing for the HIV response, helping reach the ambitious …
and regimens could be game‐changing for the HIV response, helping reach the ambitious …
PEP for HIV prevention: are we missing opportunities to reduce new infections?
J Ayieko, ML Petersen, MR Kamya… - African Journal of …, 2022 - journals.lww.com
There is newfound optimism for global efforts to reduce the estimated 1.7 million new HIV
infections still occurring every year with expanded pre-exposure prophylaxis (PrEP) access …
infections still occurring every year with expanded pre-exposure prophylaxis (PrEP) access …
Understanding how PrEP is made successful: implementation science needs an evidence-making approach
After a decade of oral HIV pre-exposure prophylaxis (PrEP), the next generation of PrEP is
being anticipated, including long-acting pills, injections, and implants. The unevenness of …
being anticipated, including long-acting pills, injections, and implants. The unevenness of …
Interrogating the promise of long-acting HIV pre-exposure prophylaxis
Oral HIV pre-exposure prophylaxis (PrEP) is a well-established product that provides a safe
and highly effective way for individuals to protect themselves against HIV infection. However …
and highly effective way for individuals to protect themselves against HIV infection. However …